{"id":"emetogenic-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Retching"}]},"_chembl":{"chemblId":"CHEMBL4297950","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Emetogenic chemotherapy is a classification of cytotoxic chemotherapy drugs (such as cisplatin, doxorubicin, and cyclophosphamide) that trigger chemotherapy-induced nausea and vomiting (CINV) through activation of chemoreceptor trigger zones and vagal afferent pathways. This is not a drug itself but rather a category describing the emetogenic potential of various chemotherapy agents used in cancer treatment.","oneSentence":"Emetogenic chemotherapy refers to chemotherapy agents that induce nausea and vomiting as a side effect, rather than a drug with a specific anti-emetic mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:10:42.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT06861010","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Pancreatic Diseases","enrollment":44},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT02106494","phase":"PHASE3","title":"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2014-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":942},{"nctId":"NCT04469556","phase":"PHASE2","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-10-14","conditions":"Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer","enrollment":150},{"nctId":"NCT04743661","phase":"PHASE2","title":"131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2022-04-04","conditions":"Recurrent Medulloblastoma, Recurrent Ependymoma","enrollment":62},{"nctId":"NCT04332874","phase":"PHASE2","title":"A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-04-01","conditions":"Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma","enrollment":30},{"nctId":"NCT07374939","phase":"PHASE2","title":"Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-03-01","conditions":"Nausea and Vomiting Chemotherapy-Induced","enrollment":50},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT05317000","phase":"PHASE2","title":"5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC","status":"RECRUITING","sponsor":"Barbara Burtness","startDate":"2023-03-23","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":50},{"nctId":"NCT07246070","phase":"PHASE2","title":"Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"AIPING ZHOU","startDate":"2025-12","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":127},{"nctId":"NCT07081256","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":665},{"nctId":"NCT05590923","phase":"PHASE4","title":"Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting","status":"TERMINATED","sponsor":"The Guthrie Clinic","startDate":"2022-12-07","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":24},{"nctId":"NCT03118986","phase":"PHASE2","title":"RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy","status":"RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2017-08-10","conditions":"Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer","enrollment":200},{"nctId":"NCT05143554","phase":"NA","title":"Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2021-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":18},{"nctId":"NCT07130617","phase":"PHASE1","title":"Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-29","conditions":"Efficacy, Safety, Megestrol Acetate","enrollment":132},{"nctId":"NCT06904235","phase":"PHASE2","title":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","status":"RECRUITING","sponsor":"Helsinn Healthcare SA","startDate":"2025-07-07","conditions":"Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy","enrollment":95},{"nctId":"NCT07035821","phase":"PHASE3","title":"Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2025-07-01","conditions":"Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer","enrollment":100},{"nctId":"NCT03448393","phase":"PHASE1","title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-26","conditions":"Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell, B-Cell Lymphoma","enrollment":54},{"nctId":"NCT05819827","phase":"","title":"Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2023-04-19","conditions":"Bladder Cancer, Prostate Cancer, Testicular Cancer","enrollment":13},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT04592198","phase":"PHASE2","title":"Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Xiamen LP Pharmaceutical Co., Ltd","startDate":"2020-10-01","conditions":"Nausea With Vomiting Chemotherapy-Induced","enrollment":22},{"nctId":"NCT06850454","phase":"PHASE3","title":"Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2025-01-10","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":140},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT04054193","phase":"PHASE4","title":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":103},{"nctId":"NCT02939287","phase":"PHASE3","title":"Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2017-09-23","conditions":"Nausea, Vomiting","enrollment":52},{"nctId":"NCT06575127","phase":"PHASE2","title":"Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2024-08-17","conditions":"Neoplasm Malignant, Colon Cancer Stage 4","enrollment":60},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT03204279","phase":"PHASE2","title":"PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2017-08-31","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":67},{"nctId":"NCT00273468","phase":"PHASE3","title":"To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2006-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":630},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT06282211","phase":"PHASE3","title":"the Efficacy and Safety of Ondansetron Oral Soluble Pellicles","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xinxiang Medical College","startDate":"2024-02-20","conditions":"Nausea and Vomiting","enrollment":184},{"nctId":"NCT04508400","phase":"PHASE2","title":"Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-08-01","conditions":"Pediatric Cancer","enrollment":108},{"nctId":"NCT05509634","phase":"PHASE3","title":"Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2022-09-21","conditions":"Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy","enrollment":754},{"nctId":"NCT06065722","phase":"PHASE2","title":"Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Simon Williamson Clinic","startDate":"2023-09-09","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":100},{"nctId":"NCT03649230","phase":"","title":"Observational Study on the Use of Akynzeo® in Patients Receiving HEC","status":"COMPLETED","sponsor":"Purdue Pharma, Canada","startDate":"2018-10-03","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":207},{"nctId":"NCT04937309","phase":"NA","title":"Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2022-06-24","conditions":"Breast Cancer","enrollment":338},{"nctId":"NCT01937156","phase":"PHASE3","title":"A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Solasia Pharma K.K.","startDate":"2013-08","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":313},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT05199818","phase":"PHASE3","title":"Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC","status":"UNKNOWN","sponsor":"Xiamen LP Pharmaceutical Co., Ltd","startDate":"2022-03-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":328},{"nctId":"NCT01022138","phase":"PHASE2","title":"Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-03-08","conditions":"Breast Cancer","enrollment":43},{"nctId":"NCT02819960","phase":"PHASE3","title":"Prevention of Irinotecan Induced Diarrhea by Probiotics","status":"COMPLETED","sponsor":"S&D Pharma SK s.r.o.","startDate":"2016-03","conditions":"Diarrhea, Cancer","enrollment":233},{"nctId":"NCT02504489","phase":"PHASE3","title":"Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2015-12","conditions":"Non-Small Cell Lung Cancer","enrollment":559},{"nctId":"NCT05346731","phase":"PHASE3","title":"Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-04-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":210},{"nctId":"NCT05275569","phase":"NA","title":"Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET)","status":"UNKNOWN","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2022-03-15","conditions":"Cancer","enrollment":234},{"nctId":"NCT04669132","phase":"PHASE2","title":"Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Instituto Brasileiro de Controle do Cancer","startDate":"2020-12-17","conditions":"Nausea Post Chemotherapy","enrollment":50},{"nctId":"NCT05230654","phase":"NA","title":"Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs","status":"UNKNOWN","sponsor":"Shanghai Children's Medical Center","startDate":"2022-02-01","conditions":"Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients","enrollment":120},{"nctId":"NCT01599520","phase":"NA","title":"Stress Management Training for Latinas Receiving Chemotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-03-13","conditions":"Cancer, Stress","enrollment":140},{"nctId":"NCT01363479","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":743},{"nctId":"NCT01346267","phase":"NA","title":"Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2011-05","conditions":"Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific","enrollment":187},{"nctId":"NCT03137121","phase":"PHASE2, PHASE3","title":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-07-12","conditions":"Advanced Cancer","enrollment":30},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT00711555","phase":"PHASE2","title":"Emend for Multiple-day Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2005-11","conditions":"Nausea, Vomiting","enrollment":22},{"nctId":"NCT01536392","phase":"PHASE3","title":"Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-03","conditions":"Cancer of the Cervix","enrollment":76},{"nctId":"NCT04912271","phase":"PHASE3","title":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-06-10","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":140},{"nctId":"NCT04411069","phase":"PHASE2","title":"Simplified Algorithm for the Prevention of Postoperative Nausea and Vomiting in an Oncological Hospital","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2019-02-20","conditions":"Postoperative Nausea, Postoperative Vomiting","enrollment":270},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT04785495","phase":"","title":"Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Instituto Brasileiro de Controle do Cancer","startDate":"2020-08-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":50},{"nctId":"NCT04651608","phase":"NA","title":"The Effect of Acupressure Chemotherapy-related Nausea Vomiting in Children","status":"COMPLETED","sponsor":"Akdeniz University","startDate":"2017-03-01","conditions":"Pediatric Cancer, Nausea With Vomiting Chemotherapy-Induced","enrollment":44},{"nctId":"NCT00967499","phase":"PHASE2","title":"Pilot Study to Assess Palonosetron Versus Ondansetron as Rescue Medication in Subjects That Develop Postoperative Nausea and Vomiting (PONV) in the Postanesthesia Care Unit (PACU)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-07-13","conditions":"Postoperative Nausea and Vomiting","enrollment":239},{"nctId":"NCT00285051","phase":"PHASE2","title":"Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy","status":"TERMINATED","sponsor":"Rafa Laboratories","startDate":"2005-11","conditions":"Cancer","enrollment":6},{"nctId":"NCT01054456","phase":"PHASE2","title":"A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-10-27","conditions":"Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC","enrollment":36},{"nctId":"NCT03177317","phase":"NA","title":"Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2017-05-01","conditions":"Colonic Neoplasms","enrollment":50},{"nctId":"NCT00588835","phase":"PHASE4","title":"Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2008-03","conditions":"Tumor","enrollment":20},{"nctId":"NCT00553059","phase":"PHASE3","title":"Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":62},{"nctId":"NCT04085393","phase":"PHASE2","title":"Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2020-08-15","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":""},{"nctId":"NCT04536558","phase":"PHASE3","title":"Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-01","conditions":"Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy","enrollment":352},{"nctId":"NCT02364804","phase":"","title":"A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shiga University","startDate":"2012-04","conditions":"Non-small Cell Lung Cancer","enrollment":10},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT04430361","phase":"PHASE2","title":"the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-09-07","conditions":"Tumor, Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT04201769","phase":"PHASE3","title":"Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2016-11-25","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":261},{"nctId":"NCT02135510","phase":"PHASE3","title":"MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-06","conditions":"Solid Tumors","enrollment":249},{"nctId":"NCT02161991","phase":"PHASE3","title":"Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers","status":"COMPLETED","sponsor":"Hunan Province Tumor Hospital","startDate":"2014-02-01","conditions":"Carcinoma, Non-small Cell Lung","enrollment":244},{"nctId":"NCT03130218","phase":"NA","title":"Aromatherapy in Management of Postoperative Nausea in Post-Bariatric Surgery Patients","status":"COMPLETED","sponsor":"Lancaster General Hospital","startDate":"2017-06-08","conditions":"Bariatric Surgery Candidate, Nausea, Postoperative","enrollment":204},{"nctId":"NCT01926236","phase":"PHASE3","title":"Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2014-02","conditions":"Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma","enrollment":162},{"nctId":"NCT03219710","phase":"PHASE3","title":"\"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)\"","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences","startDate":"2017-07-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03876938","phase":"PHASE3","title":"Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2019-03-01","conditions":"Antiemetic for Highly Emetogenic Chemotherapy","enrollment":147},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT00818259","phase":"PHASE1","title":"A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":92},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":"Chemotherapy-Induced Nausea and Vomiting (CINV)","enrollment":1015},{"nctId":"NCT02635984","phase":"PHASE3","title":"Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens","status":"COMPLETED","sponsor":"Augusta University","startDate":"2015-11","conditions":"Complications of Bone Marrow Transplant, Hematologic Neoplasms","enrollment":108},{"nctId":"NCT02672527","phase":"PHASE3","title":"Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-01-22","conditions":"Soft Tissue Sarcoma","enrollment":103},{"nctId":"NCT03606369","phase":"PHASE2, PHASE3","title":"Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-11-05","conditions":"Breast Neoplasm, Antineoplastic Agents, Antiemetics","enrollment":560},{"nctId":"NCT02517021","phase":"PHASE3","title":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-11","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":405},{"nctId":"NCT02557035","phase":"PHASE3","title":"An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-10","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":441},{"nctId":"NCT02532634","phase":"PHASE4","title":"Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2015-08-19","conditions":"Cancer, Tumors","enrollment":292},{"nctId":"NCT01698281","phase":"PHASE2","title":"Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2012-12","conditions":"Breast Cancer","enrollment":7},{"nctId":"NCT02959840","phase":"PHASE4","title":"Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-07","conditions":"Nausea, Vomiting, Satisfaction","enrollment":180},{"nctId":"NCT00431236","phase":"PHASE3","title":"A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-06","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":810},{"nctId":"NCT01993381","phase":"","title":"Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2013-11","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":80},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT02403037","phase":"NA","title":"Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients","status":"COMPLETED","sponsor":"The Hong Kong Polytechnic University","startDate":"2015-07","conditions":"Breast Neoplasms, Nausea, Vomiting","enrollment":114},{"nctId":"NCT01366599","phase":"","title":"CV Events in Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Vomiting, Cardiovascular Event, Arterial Thromboembolic Event","enrollment":12058},{"nctId":"NCT00895245","phase":"PHASE2","title":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1070,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Emetogenic chemotherapy","genericName":"Emetogenic chemotherapy","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Emetogenic chemotherapy refers to chemotherapy agents that induce nausea and vomiting as a side effect, rather than a drug with a specific anti-emetic mechanism. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}